<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Hypertens</journal-id><journal-id journal-id-type="iso-abbrev">Clin Hypertens</journal-id><journal-id journal-id-type="pmc-domain-id">2919</journal-id><journal-id journal-id-type="pmc-domain">clinhyper</journal-id><journal-id journal-id-type="publisher-id">CH</journal-id><journal-title-group><journal-title>Clinical Hypertension</journal-title></journal-title-group><issn pub-type="epub">2056-5909</issn><publisher><publisher-name>Korean Society of Hypertension</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11800288</article-id><article-id pub-id-type="pmcid-ver">PMC11800288.1</article-id><article-id pub-id-type="pmcaid">11800288</article-id><article-id pub-id-type="pmcaiid">11800288</article-id><article-id pub-id-type="pmid">39944937</article-id><article-id pub-id-type="doi">10.5646/ch.2025.31.e2</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Comorbidities that modulate temporal risk for incident hypertension among patients with obstructive sleep apnea</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6290-0475</contrib-id><name name-style="western"><surname>Te</surname><given-names initials="TT">Tue T.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="FN1" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0140-7932</contrib-id><name name-style="western"><surname>Fung</surname><given-names initials="CH">Constance H.</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8576-6408</contrib-id><name name-style="western"><surname>Boland</surname><given-names initials="MR">Mary Regina</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, <country>USA</country>.</aff><aff id="A2"><label>2</label>Geriatric, Research, Education and Clinical Center, VA Greater Los Angeles, Los Angeles, CA, <country>USA</country>.</aff><aff id="A3"><label>3</label>Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, <country>USA</country>.</aff><aff id="A4"><label>4</label>Department of Mathematics, Herbert W. Boyer School of Natural Sciences, Mathematics, and Computing, Alex G McKenna School of Business, Economics and Government, Saint Vincent College, Latrobe, PA, <country>USA</country>.</aff><author-notes><corresp>Correspondence: Tue T. Te. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA. <email>TTe@mednet.ucla.edu</email></corresp><fn id="FN1"><p><sup>&#8224;</sup>Institution where the work was performed: University of Pennsylvania.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>1</month><year>2025</year></pub-date><volume>31</volume><issue-id pub-id-type="pmc-issue-id">481517</issue-id><elocation-id>e2</elocation-id><history><date date-type="received"><day>14</day><month>4</month><year>2024</year></date><date date-type="rev-recd"><day>16</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>29</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>12</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-13 15:26:09.017"><day>13</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Korean Society of Hypertension</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Korean Society of Hypertension</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>It is identical to the Creative Commons Attribution Non-Commercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ch-31-e2.pdf"/><abstract><sec><title>Background</title><p>Our study investigates the temporality of factors that modulate the risk for developing hypertension (HTN) among patients with obstructive sleep apnea (OSA) without preexisting HTN at baseline.</p></sec><sec><title>Methods</title><p>Our cohort consisted of OSA cases (based on International Classification of Diseases, 9th/10th Revision) with 20 common comorbidities selected using a previously validated electronic health record (EHR)-based algorithm. We constructed a survival model to estimate time-to-first HTN diagnosis (among patients with OSA without preexisting HTN). Our survival model included those comorbidities along with sex, body mass index, race, and age. We also performed a validation of the date of diagnosis of OSA and HTN identified from our algorithm by utilizing chart reviews in 400 randomly chosen EHR-defined cases.</p></sec><sec><title>Results</title><p>Among 53,035 OSA cases diagnosed between 2012 and 2021, 31,741 cases (59.8%) were without preexisting HTN at the date of OSA diagnosis and thus met our inclusion criteria. Within our survival cohort, 15,830 OSA cases (50.1%) did not develop HTN. Cardiovascular conditions (including atrial fibrillation, coronary atherosclerosis, hypercholesterolemia, diabetes), tobacco use, anemia, osteoarthrosis, and gastroesophageal reflux disease were observed to increase risk of incident HTN. Allergic rhinitis, fatigue, joint pain, and vitamin D deficiency did not increase risk of incident HTN. Chart review demonstrated diagnoses of OSA and HTN were documented in notes a median of 38 days and 738 days, respectively, prior to being coded in the EHR.</p></sec><sec><title>Conclusions</title><p>In a large EHR sample, we identified conditions that are associated with increased risk of incident HTN among patients diagnosed with OSA. These findings may help guide counseling efforts among patients newly diagnosed with OSA regarding factors that may modulate risk for developing HTN.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Obstructive sleep apnea</kwd><kwd>Hypertension</kwd><kwd>Comorbidity</kwd><kwd>Electronic health records</kwd><kwd>Survival analysis</kwd><kwd>Personalized medicine</kwd><kwd>Precision medicine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="other1"><title>BACKGROUND</title><p>Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder and is known to increase morbidity and mortality [<xref rid="B1" ref-type="bibr">1</xref><xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref>]. OSA is often comorbid with cardiovascular, cerebrovascular, metabolic, and other chronic medical conditions [<xref rid="B1" ref-type="bibr">1</xref>]. Among common comorbidities related to OSA, hypertension (HTN) is the most commonly observed condition. OSA is known to increase sympathetic tone secondary to intermittent hypoxia, arousals, and changes in intrathoracic pressure [<xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref>]. Despite initial conflicting results, after over 2 decades, there is now little doubt that OSA plays an important role in developing HTN [<xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">9</xref>].</p><p>Although OSA is a risk factor for incident HTN, some patients with OSA never develop HTN. The apnea-hypopnea index (AHI) and OSA severity are predictors of incident HTN in some but not all cohort studies [<xref rid="B10" ref-type="bibr">10</xref><xref rid="B11" ref-type="bibr">11</xref><xref rid="B12" ref-type="bibr">12</xref><xref rid="B13" ref-type="bibr">13</xref><xref rid="B14" ref-type="bibr">14</xref>]. In the Sleep Heart Health Study, OSA was not a significant predictor of 5- and 7.5-year incidence of HTN after adjusting for body mass index (BMI) [<xref rid="B10" ref-type="bibr">10</xref>]. Higher BMI is one risk factor associated with both HTN and OSA, but little is known about other comorbidities that may increase risk of incident HTN in OSA populations.</p><p>Identifying modulating factors can be challenging with smaller data sets. Over the past few decades, data mining has become an integral component of knowledge discovery in medical research [<xref rid="B15" ref-type="bibr">15</xref>]. Applying these techniques to large clinical data repositories, such as the electronic health record (EHR), to identify phenotypes and associations is a particularly promising area. Sleep medicine in general&#8212;and OSA in particular&#8212;offers promising areas for applying large-scale data mining and EHR-based approaches, given the wealth of information available from overnight sleep studies and remote monitoring of treatment adherence and efficacy [<xref rid="B1" ref-type="bibr">1</xref><xref rid="B16" ref-type="bibr">16</xref><xref rid="B17" ref-type="bibr">17</xref>].</p><p>In this study, we sought to develop a new model to study comorbidities that modulate the temporal risk for incident HTN among patients with OSA diagnosis, using the 20 most common comorbidities related to OSA identified through a validated EHR-based algorithm [<xref rid="B18" ref-type="bibr">18</xref>].</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study population</title><p>We previously developed an EHR-based algorithm to classify OSA cases versus noncases, which was validated with clinical chart review across multiple sites in the United States, including the University of Pennsylvania (Penn; Philadelphia, PA, USA) [<xref rid="B19" ref-type="bibr">19</xref>]. Using our validated algorithm [<xref rid="B19" ref-type="bibr">19</xref>], patients were classified as OSA cases or noncases (controls) based on instances of OSA-related International Classification of Diseases, 9th Revision (ICD-9) codes (327.20, 327.23, 327.29, 780.51, 780.53, and 780.57) and ICD-10 codes (G4730, G4733 and G4739). Specifically, cases were defined as individuals having instances of any of these codes on at least 2 different dates in the EHR. From our other previously accepted paper, we developed algorithms to identify OSA cases in the Penn EHR system between January 1, 2008, and January 1, 2021, and top 20 most common comorbidities associated with OSA [<xref rid="B18" ref-type="bibr">18</xref>]. Adopting the complimentarily developed dataset from this study, we selected patients aged 18 years and over with first OSA diagnosis code which was under observation in EHR (e.g., &#8220;observation period&#8221;) for each case and documented in our EHR, Epic [<xref rid="B11" ref-type="bibr">11</xref><xref rid="B13" ref-type="bibr">13</xref>] from January 1, 2012, to January 1, 2021. From our previous algorithm, patients were under observation (i.e., captured in the EHR) starting on their first encounter within the health system until the earlier of either a gap of more than 3 years between successive encounters (last follow-up defined as 3 years after the last encounter date) or the end of the follow-up period (January 1, 2021) [<xref rid="B18" ref-type="bibr">18</xref>].</p></sec><sec><title>BMI</title><p>We defined BMI at the index date (e.g., date of first instance of recorded OSA diagnosis). If BMI was missing at the index date, it was defined as the mean value of all available measurements within the 6-month period between 3 months prior and 3 months post-index date. BMI was considered missing if there were no BMI measurements within the 6-month period described above.</p></sec><sec><title>Definition of comorbidities</title><p>From a previously published algorithm, using PheCodes, a comorbidity was considered present if it occurred on at least 2 different dates in the EHR during the patient&#8217;s observation period; individuals with one or fewer instances were considered not to have the associated comorbidity [<xref rid="B19" ref-type="bibr">19</xref>]. Once a person was identified as having a condition (e.g., on the date of the second instance), they were considered a prevalent case until the end of their observation period.</p><p>The top 20 most common comorbidities defined from our parent dataset included essential HTN, obesity, hyperlipidemia, pain in joint, gastroesophageal reflux disease (GERD), type 2 diabetes, morbid obesity, malaise and fatigue, tobacco use disorder, back pain, mixed hyperlipidemia, coronary atherosclerosis, hypercholesterolemia, atrial fibrillation, asthma, other anemias, osteoarthrosis, allergic rhinitis, vitamin D deficiency, and major depressive disorder [<xref rid="B18" ref-type="bibr">18</xref>].</p></sec><sec><title>Statistical analysis</title><sec><title>Survival cohort</title><p>The primary purpose of our study was to study patients with OSA without preexisting HTN at baseline OSA diagnosis using survival analysis, OSA patients with preexisting HTN were excluded from the cohort. The analysis was performed on patients with OSA aged 18 years and over who met the criteria described above and did not have HTN diagnosis (2 instances&#8217; codes for HTN documented in 2 different occurrences from January 1, 2012 to January 1, 2021) prior to OSA diagnosis. All patients entered the cohort on the day of first occurrence of OSA diagnosis code. The index date (time 0) for our survival analysis was the date of first diagnosis of OSA.</p><p>To assess the association between exposure (OSA) to outcome of interest (the risk of developing HTN), we defined censoring date as January 1, 2021. The survival time for each patient who developed HTN during the observed period was defined as the time from first OSA diagnosis to first HTN diagnosis. For patients who did not develop HTN, the censoring time was from the first code of OSA diagnosis to January 1, 2021 (our censor date). Baseline covariates including age, sex, BMI, race, and the top previously defined 20 comorbidities as specific comorbidities of interest were used for the analysis. Our final model includes covariates that were Bonferroni adjusted significant <italic toggle="yes">P</italic>-value of &#8804; 0.05.</p></sec><sec><title>Survival analysis</title><p>We used Aalen additive regression model for censored data [<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref>]. This is a survival analysis method that allows for time-varying coefficients. We analyzed the relationship using this Aalen additive regression model to study the relationship between each of the top previously defined 20 comorbidities and the risk of developing incident HTN among patients with OSA, adjusting for multiple potential confounders such as age, sex, BMI, and race.</p><p>We used backwards-selection and removed the nonsignificant covariates (<italic toggle="yes">P</italic> &#8805; 0.05) from our initial Aalen model. We then constructed a final Aalen model using this trimmed set of covariates. Finally, we applied Bonferroni correction for those factors which were significant in the final model. This resulted in one covariate that was nonsignificant after Bonferroni correction in our final model. The survival package ver. 3.5-5 [<xref rid="B22" ref-type="bibr">22</xref>] using R ver. 4.3.1 (R Foundation for Statistical Computing, Vienna, Austria) was used. All probability values were considered significant at <italic toggle="yes">P</italic> &lt; 0.05.</p></sec><sec><title>Prevalence of comorbidities in patients without preexisting HTN at baseline</title><p>We compared prevalence of comorbidities in patients without preexisting HTN between those who developed HTN after being diagnosed with OSA and those who did not. Bonferroni and false discovery rate (FDR) corrections were applied for multiple covariate analysis. All probability values were considered significant at <italic toggle="yes">P</italic> &lt; 0.001.</p></sec></sec><sec><title>Chart review</title><p>Because our survival analysis required accurate date of diagnosis both for OSA and HTN, we also performed a validation of the date of diagnosis of OSA and date of diagnosis of HTN identified from our algorithm by utilizing clinical chart reviews in 400 randomly chosen EHR-defined cases. The chart review was used to confirm the accuracy of diagnostic dates rather than directly influencing the primary outcome. A random sample of 200 cases were chosen among previously identified OSA cases using sampler package ver. 0.2.4 [<xref rid="B23" ref-type="bibr">23</xref>] in R 4.3.1 (R Foundation for Statistical Computing) and used for our OSA diagnosis date chart review. We extracted another random 200 HTN cases among OSA population (not overlapping with 200 random cases to review OSA diagnosis dates) using the same method as random OSA sample. We used the clinical notes from Penn Medicine system and other medical system whose information was available in Epic via Care Everywhere (physical notes or scanned notes).</p><p>The sample size of 400 cases was chosen to balance the need for feasibility and practical constraints, such as time and available resources. Reviewing a larger number of cases was not feasible given the scope of the study. We initially randomly selected 100 cases to validate the diagnosis date of OSA and another 100 cases (nonoverlapping) to validate the diagnosis date of HTN. We revisited our metrics every 25 patient and visualized the distribution of diagnostic dates across different categories and time periods using a density ridge plot. It provides insight into how well the algorithm aligns with clinical records by showing the density of correct versus incorrect dates. We used the outliner method to examine the characteristics of the populations (OSA, HTN) and sampled more cases until we reach the consistent results of our subset. That said, overlapping distributions or narrow confidence intervals around the expected values can indicate good performance. When our performance metrics reached the predefined criteria and additional reviews did not significantly improve the metrics. We added more cases which resulted in diminishing returns, where the performance metrics did not change substantially, it indicated that the current sample size is likely sufficient. We hence decided to stop the validation at 400 cases.</p><sec><title>OSA diagnosis chart review</title><p>Through chart reviews, we identified the first diagnostic sleep study (either in-lab polysomnogram or home sleep apnea testing [HSAT]). A sleep study was considered positive when AHI was &#8805; 5 events per hour, or respiratory disturbance index was &#8804; 5 events per hour (American Academy of Sleep Medicine guidelines) [<xref rid="B24" ref-type="bibr">24</xref>]. If a diagnostic sleep study was not available, we evaluated the clinical notes for information regarding date of diagnosis (with or without available AHI) or information regarding new positive airway pressure (PAP) treatment initiation and/or usage.</p></sec><sec><title>HTN diagnosis chart review</title><p>Similar to the algorithm for OSA, our chart reviews retrieved the first date of HTN diagnosis. If information from the clinical notes was not available, we used the first date of antihypertensive medication initiation.</p></sec><sec><title>Validating OSA cases and HTN cases among OSA cases for chart review</title><p>Within these randomly chosen samples, we compared the date of first OSA diagnosis code and the date of clinically confirmed diagnosis from chart review (either sleep study for OSA or clinical notes for HTN). The difference in time of OSA diagnosis and HTN diagnosis from the notes in Epic to the first code of OSA and HTN from our algorithm were summarized using means, standard deviations, medians, and quartiles. The mean and 95% difference between the 2 dates of diagnosis (in months) were estimated to understand the accuracy and range of potential differences supported by the data. The date of first diagnosis would be considered equivalent to a clinically confirmed date of diagnosis if the upper and lower bounds of the 95% confidence interval of the difference are within 6 months.</p></sec></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Sample characteristics of primary analysis</title><p>
<xref rid="F1" ref-type="fig">Fig. 1</xref> illustrates the generation of our survival analysis cohort from the initial set of EHR-defined OSA cases. Among 76,519 EHR-defined OSA cases, 23,484 cases (30.7%) were diagnosed with OSA prior to 2012, and 53,035 cases (69.3%) were diagnosed from 2012 to 2021. Within the subset of OSA cases with diagnosis made from 2012 to 2021 (our study population time period), there were 21,294 patients (40.2%) having HTN diagnosis at the time of OSA diagnosis, and 31,741 patients (59.8%) not having HTN diagnosis at the time of OSA diagnosis. Our study includes OSA patients diagnosed between 2012&#8211;2021 having no HTN at initial OSA diagnosis and therefore our cohort comprises 31,741 patients without preexisting HTN diagnosis that were selected for the analysis.</p><fig position="float" fig-type="figure" id="F1" orientation="portrait"><label>Fig. 1</label><caption><title>Flow diagram of cases included in the survival analysis subset.</title><p>EHR, electronic health record; OSA, obstructive sleep apnea; HTN, hypertension.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ch-31-e2-g001.jpg"/></fig></sec><sec><title>Temporality of factors that modulate the risk for developing HTN</title><p>Among our survival study cohort (31,741 patients), the median age of 55 years (interquartile range [IQR], 44 to 65 years) with more men (60.9%) than women (39.1%). The subset had a median BMI of 35.2 kg/m<sup>2</sup> (IQR, 29.0 to 40.0 kg/m<sup>2</sup>) classified as class 2 obesity. Among 31,471 patients, 3,017 (9.5%) were missing data on BMI (<xref rid="T1" ref-type="table">Table 1</xref>). Being observed over the course of time following their initial OSA diagnosis, the total number of patients developing HTN (49.9%) was almost equal to those not developing HTN (50.1%). Our Aalen additive regression model showed that age, race (only Black was statistically different from White), sex, BMI, atrial fibrillation, coronary atherosclerosis, tobacco use, other anemias, type 2 diabetes, vitamin D deficiency, hyperlipidemia, hypercholesterolemia, osteoarthrosis, allergic rhinitis, GERD, malaise and fatigue, joint pain were statistically significant (<italic toggle="yes">P</italic> &lt; 0.05). Among those covariates, age, Black race, male sex, BMI, atrial fibrillation, coronary atherosclerosis, pure hyperlipidemia, hypercholesterolemia, GERD, type 2 diabetes, tobacco use, other anemia, osteoarthrosis appeared to increase risk of incident HTN. Allergic rhinitis, malaise and fatigue, joint pain, and vitamin D deficiency were observed not to increase HTN development (<xref rid="F2" ref-type="fig">Fig. 2</xref>). We applied Bonferroni correction for those factors which were significant in the Aalen additive regression model. This resulted in one covariate that was nonsignificant after Bonferroni correction in our final model that is back pain; therefore, back pain was removed from our final Aalen regression model. Other factors remained significant after the Bonferroni correction. The coefficients of all covariates generated from Aalen additive regression model are presented in <xref rid="T2" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Characteristics of OSA without preexisting HTN diagnosis (survival cohort)</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ch-31-e2-i001.jpg"/><table frame="hsides" rules="rows"><col width="3.29%" span="1"/><col width="35.33%" span="1"/><col width="61.38%" span="1"/><thead><tr><th align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Characteristic</th><th align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">OSA without preexisting HTN diagnosis (<italic toggle="yes">N</italic> = 31,741)</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1" valign="top">Age (yr)<sup>a</sup>
</td><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Mean &#177; SD</td><td align="center" colspan="1" rowspan="1" valign="top">54.0 &#177; 14.5</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Median (IQR)</td><td align="center" colspan="1" rowspan="1" valign="top">55.0 (44.0&#8211;65.0)</td></tr><tr><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Sex</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Female</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">12,418 (39.1)</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Male</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">19,323 (60.9)</td></tr><tr><td align="left" colspan="2" rowspan="1" valign="top">Body mass index<sup>b</sup> (kg/m<sup>2</sup>)</td><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Mean &#177; SD</td><td align="center" colspan="1" rowspan="1" valign="top">35.2 &#177; 9.0</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Median (IQR)</td><td align="center" colspan="1" rowspan="1" valign="top">35.2 (29.0&#8211;40.0)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Missing</td><td align="center" colspan="1" rowspan="1" valign="top">3,017 (9.5)</td></tr></tbody></table></alternatives><table-wrap-foot><p>Data are presented as number (%), unless otherwise indicated.</p><p>OSA, obstructive sleep apnea; HTN, hypertensin; SD, standard deviation; IQR, interquartile range.</p><p><sup>a</sup>Age of diagnosis for OSA cases.</p><p><sup>b</sup>Body mass index at date of diagnosis for OSA cases or (&#177; 6 months) of diagnosis for OSA cases.</p></table-wrap-foot></table-wrap><fig position="float" fig-type="figure" id="F2" orientation="portrait"><label>Fig. 2</label><caption><title>The predictive probability of developing hypertension over an 8-year period: by comorbidity at time of obstructive sleep apnea diagnosis (survival analysis using Aalen additive regression model for censored data, <italic toggle="yes">n</italic> = 31,741). A positive coefficient for a covariate suggests that as the covariate increases, the cumulative hazard function increases, indicating an increased risk of the event. A negative coefficient suggests that as the covariate increases, the cumulative hazard function decreases, indicating a decreased risk of the event.</title><p>GERD, gastroesophageal reflux disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ch-31-e2-g002.jpg"/></fig><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><title>Aalen additive regression model results (survival cohort)</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ch-31-e2-i002.jpg"/><table frame="hsides" rules="rows"><col width="4.56%" span="1"/><col width="56.43%" span="1"/><col width="39%" span="1"/><thead><tr><th align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Covariate</th><th align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Coefficient</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1" valign="top">Intercept</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;7.31 &#215; 10<sup>&#8722;5</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Age</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">1.0 &#215; 10<sup>&#8722;6</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" valign="top">Race</td><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Black or African American</td><td align="center" colspan="1" rowspan="1" valign="top">1.25 &#215; 10<sup>&#8722;</sup>
<sup>5</sup>
</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Asian</td><td align="center" colspan="1" rowspan="1" valign="top">3.5 &#215; 10<sup>&#8722;5</sup>
</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Other</td><td align="center" colspan="1" rowspan="1" valign="top">1.1 &#215; 10<sup>&#8722;6</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Male sex</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">8.2 &#215; 10<sup>&#8722;6</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" valign="top">Body mass index</td><td align="center" colspan="1" rowspan="1" valign="top">1.3 &#215; 10<sup>&#8722;6</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Hyperlipidemia</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">1.27 &#215; 10<sup>&#8722;5</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" valign="top">Pain in joint</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;6.5 &#215; 10<sup>&#8722;6</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Gastroesophageal reflux disease</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2.6 &#215; 10<sup>&#8722;6</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" valign="top">Type 2 diabetes</td><td align="center" colspan="1" rowspan="1" valign="top">2.33 &#215; 10<sup>&#8722;5</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Malaise and fatigue</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;4.9 &#215; 10<sup>&#8722;6</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" valign="top">Tobacco use disorder</td><td align="center" colspan="1" rowspan="1" valign="top">6.3 &#215; 10<sup>&#8722;6</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Coronary atherosclerosis</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">1.63 &#215; 10<sup>&#8722;5</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" valign="top">Hypercholesterolemia</td><td align="center" colspan="1" rowspan="1" valign="top">4.6 &#215; 10<sup>&#8722;6</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Atrial fibrillation</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">1.12 &#215; 10<sup>&#8722;5</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" valign="top">Other anemias</td><td align="center" colspan="1" rowspan="1" valign="top">5.8 &#215; 10<sup>&#8722;6</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Osteoarthrosis (localized, primary)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">3.9 &#215; 10<sup>&#8722;6</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" valign="top">Allergic rhinitis</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;6.9 &#215; 10<sup>&#8722;6</sup>
</td></tr><tr><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Vitamin D deficiency</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;8.6 &#215; 10<sup>&#8722;6</sup>
</td></tr></tbody></table></alternatives></table-wrap></sec><sec><title>Prevalence of most common comorbidities in without preexisting HTN subsets</title><p>Comparison between prevalence of comorbidities in those who developed HTN after being diagnosed with OSA and those who did not develop HTN was presented in <xref rid="T3" ref-type="table">Table 3</xref>. Generally, a higher prevalence of most comorbidities was observed in patients who developed HTN within the 9-year follow-up period. The prevalence of these comorbidities ranged from 13.6% to 51.5% in the subset of patients who developed HTN post-OSA, and from 8.6% to 37.0% in the subset who did not develop HTN post-OSA. Among all comorbidities, the following were notably higher in patients who developed HTN post-OSA: obesity, hyperlipidemia, GERD, type 2 diabetes, morbid obesity, tobacco use, back pain, mixed hyperlipidemia, coronary atherosclerosis, hypercholesterolemia, atrial fibrillation, other anemia, osteoarthrosis, and major depressive disorder. Conversely, pain in joints, malaise and fatigue, asthma, allergic rhinitis, and vitamin D deficiency were less prevalent in the subset who did not develop HTN post-OSA. Hyperlipidemia (51.5%), obesity (50.6%), and GERD (38.6%) had the highest prevalence in the group that developed HTN post-OSA. These prevalences were statistically significant with <italic toggle="yes">P</italic>-values of &lt; 0.001 after applying Bonferroni and FDR corrections.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><title>Prevalence of most common comorbidities in subsets without preexisting HTN at the time of OSA diagnosis</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ch-31-e2-i003.jpg"/><table frame="hsides" rules="rows"><col width="24.79%" span="1"/><col width="10.08%" span="1"/><col width="17.44%" span="1"/><col width="19.54%" span="1"/><col width="20.59%" span="1"/><col width="7.56%" span="1"/><thead><tr><th align="left" colspan="1" rowspan="2" style="background-color:rgb(233,231,243)" valign="top">Comorbidity</th><th align="center" colspan="1" rowspan="2" style="background-color:rgb(233,231,243)" valign="top">PheCode</th><th align="center" colspan="3" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">No. of cases (%)</th><th align="center" colspan="1" rowspan="2" style="background-color:rgb(233,231,243)" valign="top"><italic toggle="yes">P</italic>-value<sup>a</sup></th></tr><tr><th align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Total (<italic toggle="yes">N</italic> = 31,741)</th><th align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Not developed HTN post-OSA (<italic toggle="yes">n</italic> = 15,911, 50.1%)</th><th align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Developed HTN post-OSA (<italic toggle="yes">n</italic> = 15,830, 49.9%)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1" valign="top">Obesity</td><td align="center" colspan="1" rowspan="1" valign="top">278.1</td><td align="center" colspan="1" rowspan="1" valign="top">13,895 (43.8)</td><td align="center" colspan="1" rowspan="1" valign="top">5,892 (37.0)</td><td align="center" colspan="1" rowspan="1" valign="top">8,003 (50.6)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Hyperlipidemia</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">272.1</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">12,286 (38.7)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">4,141 (26.0)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">8,145 (51.5)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Pain in joint</td><td align="center" colspan="1" rowspan="1" valign="top">745</td><td align="center" colspan="1" rowspan="1" valign="top">10,908 (34.4)</td><td align="center" colspan="1" rowspan="1" valign="top">5,560 (34.9)</td><td align="center" colspan="1" rowspan="1" valign="top">5,348 (33.8)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">GERD</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">530.11</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">11,197 (35.2)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">5,089 (32.0)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">6,108 (38.6)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Type 2 diabetes</td><td align="center" colspan="1" rowspan="1" valign="top">250.2</td><td align="center" colspan="1" rowspan="1" valign="top">7,970 (25.1)</td><td align="center" colspan="1" rowspan="1" valign="top">1,910 (12.0)</td><td align="center" colspan="1" rowspan="1" valign="top">6,060 (38.3)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Morbid obesity</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">278.11</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">8,622 (27.2)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">3,428 (21.5)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">5,194 (32.8)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Malaise and fatigue</td><td align="center" colspan="1" rowspan="1" valign="top">798</td><td align="center" colspan="1" rowspan="1" valign="top">8,978 (28.3)</td><td align="center" colspan="1" rowspan="1" valign="top">4,554 (28.6)</td><td align="center" colspan="1" rowspan="1" valign="top">4,424 (27.9)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Tobacco use disorder</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">318</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">7,945 (25.0)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2,911 (18.3)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">5,034 (31.8)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Back pain</td><td align="center" colspan="1" rowspan="1" valign="top">760</td><td align="center" colspan="1" rowspan="1" valign="top">7,592 (23.9)</td><td align="center" colspan="1" rowspan="1" valign="top">3,774 (23.7)</td><td align="center" colspan="1" rowspan="1" valign="top">3,818 (24.1)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Mixed hyperlipidemia</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">272.13</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">6,294 (19.8)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2,518 (15.8)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">3,776 (23.9)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Coronary atherosclerosis</td><td align="center" colspan="1" rowspan="1" valign="top">411.4</td><td align="center" colspan="1" rowspan="1" valign="top">5,867 (18.5)</td><td align="center" colspan="1" rowspan="1" valign="top">1,319 (8.3)</td><td align="center" colspan="1" rowspan="1" valign="top">4,548 (28.7)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Hypercholesterolemia</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">272.11</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">6,962 (21.9)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2,604 (16.4)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">4,358 (27.5)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Atrial fibrillation</td><td align="center" colspan="1" rowspan="1" valign="top">427.21</td><td align="center" colspan="1" rowspan="1" valign="top">5,165 (16.3)</td><td align="center" colspan="1" rowspan="1" valign="top">1,365 (8.6)</td><td align="center" colspan="1" rowspan="1" valign="top">3,800 (24.0)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Asthma</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">495</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">6,155 (19.4)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">3,142 (19.7)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">3,013 (19.0)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Other anemias</td><td align="center" colspan="1" rowspan="1" valign="top">285</td><td align="center" colspan="1" rowspan="1" valign="top">5,204 (16.4)</td><td align="center" colspan="1" rowspan="1" valign="top">1,837 (11.5)</td><td align="center" colspan="1" rowspan="1" valign="top">3,367 (21.3)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Osteoarthrosis (localized, primary)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">740.11</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">5,114 (16.1)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">1,985 (12.5)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">3,129 (19.8)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Allergic rhinitis</td><td align="center" colspan="1" rowspan="1" valign="top">476</td><td align="center" colspan="1" rowspan="1" valign="top">6,325 (19.9)</td><td align="center" colspan="1" rowspan="1" valign="top">3,797 (23.9)</td><td align="center" colspan="1" rowspan="1" valign="top">2,528 (16.0)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Vitamin D deficiency</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">261.4</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">4,804 (15.1)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2,659 (16.7)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2,145 (13.6)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Major depressive disorder</td><td align="center" colspan="1" rowspan="1" valign="top">296.22</td><td align="center" colspan="1" rowspan="1" valign="top">5,943 (18.7)</td><td align="center" colspan="1" rowspan="1" valign="top">2,928 (18.4)</td><td align="center" colspan="1" rowspan="1" valign="top">3,015 (19.0)</td><td align="center" colspan="1" rowspan="1" valign="top">&lt; 0.001</td></tr></tbody></table></alternatives><table-wrap-foot><p>HTN, hypertension; OSA, obstructive sleep apnea; GERD, gastroesophageal reflux disease.</p><p><sup>a</sup>All <italic toggle="yes">P</italic> &lt; 0.001 after Bonferroni and false discovery rate corrections.</p></table-wrap-foot></table-wrap></sec><sec><title>Chart review</title><sec><title>Sample characteristics of chart review subsets</title><p>
<xref rid="F3" ref-type="fig">Fig. 3</xref> illustrates the OSA chart review subset from the initial set of randomly sample of 200 cases. Among 200 cases, 57 cases were excluded due to missing information (e.g., sleep study and/or diagnosis date) in the notes, resulting in 143 OSA cases diagnosed from 2008 to 2021 and subsequently 111 cases diagnosed from 2012 to 2021 were selected as subset to validate the offset of diagnosis date established in the notes and from our algorithm. Among the OSA validating subset, 88.3% had information from either first sleep study (gold standard) or clinical notes mention diagnosis date.</p><fig position="float" fig-type="figure" id="F3" orientation="portrait"><label>Fig. 3</label><caption><title>Distribution of difference in obstructive sleep apnea diagnosis date between first sleep study date and electronic health record-based algorithm. The peaks of each histogram represent the mode (most common number) of patients having that result. Peaks at 0 are desirable indicating that the majority of the data did not differ between the diagnosis date and the chart review true diagnosis date. If the histograms drift from 0 that indicates that there is a difference between the diagnosis date and the chart review diagnosis date.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ch-31-e2-g003.jpg"/></fig><p>
<xref rid="F4" ref-type="fig">Fig. 4</xref> illustrates the HTN chart review subset from the initial set of randomly sample of 200 cases. Among 200 cases, 60 cases were excluded due to missing information (e.g., &#8220;clinical notes mention diagnosis date&#8221; and/or &#8220;antihypertensive medication first start date&#8221;) in the notes, resulting in 140 OSA cases with HTN diagnosed from 2008 to 2021 and subsequently 87 cases diagnosed from 2012 to 2021 were selected as subset to validate the offset of diagnosis date established in the notes and from our algorithm. Among the HTN validating subset, 100% had information from having either diagnosis date in notes or &#8220;antihypertensive medication first start date.&#8221;</p><fig position="float" fig-type="figure" id="F4" orientation="portrait"><label>Fig. 4</label><caption><title>Distribution of difference in HTN diagnosis date between clinical note and electronic health record-based algorithm. The peaks of each histogram represent the mode (most common number) of patients having that result. Peaks at 0 are desirable indicating that the majority of the data did not differ between the diagnosis date and the chart review true diagnosis date. If the histograms drift from 0 that indicates that there is a difference between the diagnosis date and the chart review diagnosis date.</title><p>HTN, hypertension.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ch-31-e2-g004.jpg"/></fig><p>
<xref rid="T4" ref-type="table">Table 4</xref> described the characteristics of both OSA and HTN chart reviews subsets. The subset of patients in the OSA chart review with diagnosis dates between 2012 and 2021 was slightly older than the subset of patients in the HTN chart review, with median age of 66 years (IQR, 57 to 71 years) and 61 years (IQR, 50 to 67 years), respectively. The OSA subset had a lower BMI (median, 32.0 kg/m<sup>2</sup>; IQR, 29.5 to 39.0 kg/m<sup>2</sup>) than the HTN subset (median BMI, 36.0 kg/m<sup>2</sup>; IQR, 30.1 to 43.8 kg/m<sup>2</sup>). Within the OSA subset, the percentage of patients having first sleep study date was similar to the percentage of patients having &#8220;clinical notes mention diagnosis date.&#8221; Within the HTN subset, the percentage of patients having &#8220;clinical notes mention HTN diagnosis date&#8221; was much higher (92.0%) than the percentage of patients having an antihypertensive medication first start date (34.5%). The characteristics of OSA and HTN subsets with diagnosis dates between 2008 and 2021 was similar to the subset with diagnosis dates between 2012 to 2021.</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><title>Characteristics of chart review subsets</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ch-31-e2-i004.jpg"/><table frame="hsides" rules="rows"><col width="2.06%" span="1"/><col width="2.06%" span="1"/><col width="36.82%" span="1"/><col width="14.95%" span="1"/><col width="14.95%" span="1"/><col width="14.95%" span="1"/><col width="14.21%" span="1"/><thead><tr><th align="left" colspan="3" rowspan="2" style="background-color:rgb(233,231,243)" valign="top">Characteristic</th><th align="center" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">OSA diagnosis year</th><th align="center" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">HTN diagnosis year</th></tr><tr><th align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2008&#8211;2021 (<italic toggle="yes">n</italic> = 143)</th><th align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2012&#8211;2021 (<italic toggle="yes">n</italic> = 111)</th><th align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2008&#8211;2021 (<italic toggle="yes">n</italic> = 140)</th><th align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2012&#8211;2021 (<italic toggle="yes">n</italic> = 87)</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1" valign="top">Age<sup>a</sup> (yr)</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="2" rowspan="1" valign="top">Mean &#177; SD</td><td align="center" colspan="1" rowspan="1" valign="top">66.7 &#177; 12.8</td><td align="center" colspan="1" rowspan="1" valign="top">63.3 &#177; 12.8</td><td align="center" colspan="1" rowspan="1" valign="top">58.3 &#177; 12.5</td><td align="center" colspan="1" rowspan="1" valign="top">59.1 &#177; 12.8</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="2" rowspan="1" valign="top">Median (IQR)</td><td align="center" colspan="1" rowspan="1" valign="top">64.6 (54.5&#8211;69.9)</td><td align="center" colspan="1" rowspan="1" valign="top">66.4 (56.9&#8211;71.1)</td><td align="center" colspan="1" rowspan="1" valign="top">58.3 (50.0&#8211;67.0)</td><td align="center" colspan="1" rowspan="1" valign="top">61.0 (50.0&#8211;67.0)</td></tr><tr><td align="left" colspan="3" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Sex</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Female</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">65 (45.4)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">50 (45.0)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">60 (42.9)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">36 (41.4)</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Male</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">78 (54.5)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">61 (55.0)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">80 (57.1)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">51 (58.6)</td></tr><tr><td align="left" colspan="3" rowspan="1" valign="top">Body mass index<sup>b</sup> (kg/m<sup>2</sup>)</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="2" rowspan="1" valign="top">Mean &#177; SD</td><td align="center" colspan="1" rowspan="1" valign="top">33.9 &#177; 6.7</td><td align="center" colspan="1" rowspan="1" valign="top">33.8 &#177; 6.7</td><td align="center" colspan="1" rowspan="1" valign="top">37.8 &#177; 10.6</td><td align="center" colspan="1" rowspan="1" valign="top">38.4 &#177; 11.0</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="2" rowspan="1" valign="top">Median (IQR)</td><td align="center" colspan="1" rowspan="1" valign="top">32.8 (29.8&#8211;39.0)</td><td align="center" colspan="1" rowspan="1" valign="top">32.0 (29.5&#8211;39.0)</td><td align="center" colspan="1" rowspan="1" valign="top">36.0 (30.0&#8211;43.0)</td><td align="center" colspan="1" rowspan="1" valign="top">36.0 (30.1&#8211;43.8)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="2" rowspan="1" valign="top">Missing</td><td align="center" colspan="1" rowspan="1" valign="top">31 (21.6)</td><td align="center" colspan="1" rowspan="1" valign="top">13 (11.7)</td><td align="center" colspan="1" rowspan="1" valign="top">36 (25.7)</td><td align="center" colspan="1" rowspan="1" valign="top">17 (19.5)</td></tr><tr><td align="left" colspan="3" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Validation sample</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">OSA</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">(1) Having first sleep study date</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">86 (60.1)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">71 (64.0)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">(2) Having notes mentioning diagnosis date</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">97 (67.8)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">71 (64.0)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Missing either (1) or (2)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">17 (11.9)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">13 (11.7)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">HTN</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">(1) Having notes mentioning HTN diagnosis date</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">130 (92.9)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">80 (92.0)</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">(2) Having antihypertensive medication first start date</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">66 (47.1)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">30 (34.5)</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Missing either (1) or (2)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">0 (0)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">0 (0)</td></tr></tbody></table></alternatives><table-wrap-foot><p>Data are presented as number (%), unless otherwise indicated.</p><p>OSA, obstructive sleep apnea; HTN, hypertension; SD, standard deviation; IQR, interquartile range.</p><p><sup>a</sup>Age of diagnosis for OSA cases.</p><p><sup>b</sup>Body mass index at date of diagnosis for OSA cases or (&#177; 6 months) of diagnosis for OSA cases.</p></table-wrap-foot></table-wrap><p>For the patients with OSA diagnosed between 2012 and 2021 in the chart review subset, the median of difference between first sleep study to diagnosis date in our algorithm was &#8722;38 days (IQR, &#8722;117 to 12 days), which suggests that the OSA diagnosis date in the sleep study was 38 days prior to the first code in our algorithm (<xref rid="T5" ref-type="table">Table 5</xref>). Similarly, the median of difference between diagnosis dates in clinical notes to diagnosis date in our algorithm for our HTN chart review subset was &#8722;738 days (IQR, &#8722;1,292 to &#8722;358 days), which suggests that the HTN diagnosis date in &#8220;clinical notes mention diagnosis date&#8221; and/or antihypertensive medication first start date occurred 738 days prior to the date captured in Epic.</p><table-wrap position="float" id="T5" orientation="portrait"><label>Table 5</label><caption><title>Difference in diagnosis date between sleep study or notes in Epic and EHR-based ALG</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ch-31-e2-i005.jpg"/><table frame="hsides" rules="rows"><col width="2.02%" span="1"/><col width="2.02%" span="1"/><col width="20.77%" span="1"/><col width="19.49%" span="1"/><col width="18.57%" span="1"/><col width="19.12%" span="1"/><col width="18.01%" span="1"/><thead><tr><th align="left" colspan="3" rowspan="2" style="background-color:rgb(233,231,243)" valign="top">Difference in time</th><th align="center" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">OSA diagnosis year</th><th align="center" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">HTN diagnosis year</th></tr><tr><th align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2008&#8211;2021 (<italic toggle="yes">n</italic> = 143)</th><th align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2012&#8211;2021 (<italic toggle="yes">n</italic> = 111)</th><th align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2008&#8211;2021 (<italic toggle="yes">n</italic> = 140)</th><th align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">2012&#8211;2021 (<italic toggle="yes">n</italic> = 87)</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1" valign="top">OSA</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="2" rowspan="1" valign="top">(1) From sleep study (Epic) to diagnosis date (ALG) (day)</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top">-</td><td align="center" colspan="1" rowspan="1" valign="top">-</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Mean &#177; SD</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;808 &#177; 1,320</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;650 &#177; 1,427.6</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Median (IQR)</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;76.5 (&#8722;1,159.25 to 2.50)</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;38.0 (&#8722;1,117.5 to 12.0)</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Missing</td><td align="center" colspan="1" rowspan="1" valign="top">57 (39.9)</td><td align="center" colspan="1" rowspan="1" valign="top">40 (36)</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="2" rowspan="1" valign="top">(2) Diagnosis date (note/Epic) to diagnosis date (ALG) (day)</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top">-</td><td align="center" colspan="1" rowspan="1" valign="top">-</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Mean &#177; SD</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;1,210.0 &#177; 0</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;1,169.2 &#177; 1,515.4</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Median (IQR)</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;543.5 (&#8722;1,877.0 to &#8722;102.0)</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;502.0 (&#8722;1,790.5 to &#8722;76.5)</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Missing</td><td align="center" colspan="1" rowspan="1" valign="top">46 (32.2)</td><td align="center" colspan="1" rowspan="1" valign="top">40 (36.0)</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="2" rowspan="1" valign="top">From earliest date among (1) or (2) to diagnosis date (ALG) (day)</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top">-</td><td align="center" colspan="1" rowspan="1" valign="top">-</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Mean &#177; SD</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;1,210.0 &#177; 1,464.0</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;1,232.0 &#177; 1,528.6</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Median (IQR)</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;562.5 (&#8722;2,164.5 to &#8722;63.75)</td><td align="center" colspan="1" rowspan="1" valign="top">&#8722;537.5 (&#8722;2,164.5 to &#8722;50.5)</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Missing</td><td align="center" colspan="1" rowspan="1" valign="top">17 (11.9)</td><td align="center" colspan="1" rowspan="1" valign="top">13 (11.7)</td><td align="center" colspan="1" rowspan="1" valign="top"/><td align="center" colspan="1" rowspan="1" valign="top"/></tr><tr><td align="left" colspan="3" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">HTN</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">(1) From diagnosis date (note/Epic) to diagnosis date (ALG) (day)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Mean &#177; SD</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;1,723.8 &#177; 2,036.4</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;1,165.0 &#177; 1,319.1</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Median (IQR)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;1,067.5 (&#8722;2,283.5 to &#8722;432.5)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;738.5 (&#8722;1,292.5 to &#8722;358.25)</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Missing</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">10 (7.1)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">7 (8.0)</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">(2) From antihypertensive medication first start date (Epic) to diagnosis date (ALG) (day)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Mean &#177; SD</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;961.3 &#177; 1,271.4</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;931.3 &#177; 1,166.5</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Median (IQR)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;380.5 (&#8722;1,702.25 to 0)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;380.5 (&#8722;1,659.25 to &#8722;8.0)</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Missing</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">74 (52.9)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">57 (65.5)</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="2" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">From earliest date among (1) or (2) to diagnosis date (ALG) (day)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">-</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Mean &#177; SD</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;1,693.0 &#177; 1,991.2</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;1,187.1 &#177; 1,317.1</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Median (IQR)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;1,037.0 (&#8722;2,298.25 to &#8722;417.0)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">&#8722;735.0 (&#8722;1,369.0 to &#8722;378.0)</td></tr><tr><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="left" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">Missing</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top"/><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">0 (0)</td><td align="center" colspan="1" rowspan="1" style="background-color:rgb(233,231,243)" valign="top">0 (0)</td></tr></tbody></table></alternatives><table-wrap-foot><p>Data are presented as number (%), unless otherwise indicated. The minus signs among the dates indicate that the date of diagnosis in the EHR was after the true diagnosis date revealed in the clinical notes.</p><p>EHR, electronic health record; ALG, algorithm; OSA, obstructive sleep apnea; HTN, hypertension; SD, standard deviation; IQR, interquartile range.</p></table-wrap-foot></table-wrap></sec></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>We analyzed a large data set of patients with OSA to determine whether specific conditions that commonly coexist with OSA are associated with an increased risk of developing HTN (which occurred in 49.9% of patients with OSA). In an Aalen&#8217;s additive regression model that adjusted for age, sex, race, and BMI, we found that cardiovascular conditions (including atrial fibrillation, coronary atherosclerosis, hypercholesterolemia, and diabetes), tobacco use, anemia, osteoarthrosis, and GERD were observed to increase risk of incident HTN. In contrast, allergic rhinitis, fatigue, joint pain, and vitamin D deficiency did not increase risk of incident HTN. These findings align with our other results, showing that among all comorbidities, the following were notably higher at baseline at the time of OSA diagnosis in patients who developed HTN after being diagnosed with OSA: obesity, hyperlipidemia, GERD, type 2 diabetes, morbid obesity, tobacco use, back pain, mixed hyperlipidemia, coronary atherosclerosis, hypercholesterolemia, atrial fibrillation, other anemia, osteoarthrosis, and major depressive disorder. Conversely, pain in joints, malaise and fatigue, asthma, allergic rhinitis, and vitamin D deficiency were less prevalent at baseline at the time of OSA diagnosis in the subset who did not develop HTN post-OSA. Our findings can provide guidance to patients with newly diagnosed OSA about their risk of HTN development and could potentially help clinicians personalize the counseling they deliver to patients with newly diagnosed OSA about HTN and blood pressure (BP) monitoring.</p><p>Several cohort studies have examined factors among patients with OSA that predict incident HTN. The Sleep Heart Health Study (<italic toggle="yes">n</italic> = 2,470) found that the AHI was not a significant predictor of 5- and 7.5-year incident HTN after adjusting for BMI [<xref rid="B10" ref-type="bibr">10</xref>]. In the Wisconsin Sleep Cohort Study (<italic toggle="yes">n</italic> = 709), investigators found that higher AHI was associated with increased odds of developing HTN over an 8-year period as well as blunting of the normal nocturnal lowering of systolic BP (nondipping) after adjusting for variables such as age, sex, and BMI (<italic toggle="yes">n</italic> = 328) [<xref rid="B13" ref-type="bibr">13</xref>]. Similarly, in the Zaragoza Sleep Cohort Study, OSA was associated with incident HTN after adjusting for AHI, age, sex, BMI, and baseline BP among patients without HTN referred to a sleep center (<italic toggle="yes">n</italic> = 1,889) [<xref rid="B12" ref-type="bibr">12</xref>]. The Vitoria Sleep Cohort study (<italic toggle="yes">n</italic> = 2,148) found no association between OSA and incident HTN (over a 7- to 8-year follow-up period) after adjusting for sex, BMI, neck circumference, fitness level, alcohol, tobacco, and coffee consumption [<xref rid="B11" ref-type="bibr">11</xref>]. These large cohort studies, however, did not have the sample sizes that are available in a big data study that uses EHR such as our study (<italic toggle="yes">n</italic> = 53,035), which can support inclusion of a larger number of covariates in statistical models. Our study is one of the first to examine on how multiple comorbidities modulate risk for incident HTN among patients with OSA over a several year follow-up period.</p><p>One of our main findings is that cardiovascular burden increases the temporal risk for developing HTN, independent of age, sex, and BMI. This finding aligns with mechanistic studies that have examined the role of increased sympathetic tone, inflammation, endothelial dysfunction, peripheral vasoconstriction, increased the renin-angiotensin-aldosterone system, heightened chemoreflex, and blunted baroreflex sensitivity [<xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref>] in the development of HTN in populations with OSA. We found that type 2 diabetes increases the risk of developing HTN in those with OSA at baseline diagnosis. There is a well-known relationship between type 2 diabetes and increased risk of HTN, through endothelial dysfunction caused by diabetes that leads to fluid retention, which can raise BP [<xref rid="B25" ref-type="bibr">25</xref>].</p><p>Another finding from our study is related to the documentation of OSA in the EHR. In our study, the clinical chart review demonstrated that OSA diagnosis was documented in notes a median of 38 days prior to being coded in the EHR. We speculate that this delay may be due to a subset of patients who are seen by providers outside of the healthcare system and who transferred care further management. When patients transfer care from providers outside the healthcare system to internal providers, the internal providers need to reconcile the patients&#8217; problem list. However, the date when the providers first reconcile their patient&#8217;s diagnosis would be the date of the diagnosis as default unless the providers specify otherwise. Therefore, a particular diagnosis could be made by an outside provider prior to the date when diagnosis code is captured in the EHR. Also, the clinical chart review demonstrated that HTN diagnosis was documented in notes a median of 738 days prior to being coded in the EHR. Similar to OSA chart review, this could have the same issues as discussed above. In addition, HTN is one of the most common chronic conditions and providers might prioritize documenting less common or more acute conditions over well-known chronic conditions like HTN. We speculate that clinicians may delay documenting this condition because of its commonality [<xref rid="B26" ref-type="bibr">26</xref>].</p><p>Our study has several strengths. Our survival cohort was conducted with a large sample and longer followed period. It also provided better capture of health care utilizations from the wide range of both inpatient and outpatient settings. Narrowing the follow-up years mitigated potential biases due to loss of data capture at the beginning of Epic use. The commonly known confounders including age, sex, race, and BMI were controlled to reduce potential biases. Moreover, true diagnosis dates of OSA and HTN were validated in a large sample of chart review. The chart review was carefully performed by a sleep medicine physician who was familiar with Epic structure at the healthcare system and with commonly used sleep medicine acronyms and abbreviations, that likely increased accuracy for the procedures. Finally, we applied the robust survival analysis approach&#8212;Aalen additive regression model&#8212;to investigate factors that modulate temporal risks for developing new HTN among patients with OSA, that provides new insights into disease heterogeneity and potential personalized medicine approaches.</p><p>Our study is an observational study and can only show associations, not causation. Additional limitations of our study include the lack of information on OSA treatment including PAP and oral appliance use, and baseline BP, and AHI. Our study design examined comorbidities at the time of OSA diagnosis and their risk of incident HTN over 9 years from January 2012 to January 2021; the extent to which patients adhered to OSA treatment and the effects of OSA treatment on the risk of incident HTN could not be modeled with our data set. While these specific metrics were not included, we believe that several aspects of our study design and data collection process help mitigate the potential biases associated with these missing variables. First, although AHI and BP were not available, we incorporated potentially confounding variables including age, sex, BMI, and race that were available in our dataset into our survival analysis model to adjust for their effects. Fattal et al. [<xref rid="B27" ref-type="bibr">27</xref>] found &#8220;a simple mathematical relationship between BMI and AHI: for every 1-point drop in BMI, AHI decreases by 6.2%,&#8221; although we acknowledge that others have not found a significant relationship. The inclusion of potentially confounding variables helps to account for some of the key risk factors known to influence HTN development. Second, the large sample size of our cohort increases the statistical power of our study and improves the generalizability of our findings. A larger cohort is also more likely to capture a diverse range of health profiles (e.g., cardiovascular risks, obesity, etc.). By including data from a wide range of both inpatient and outpatient settings, we ensure a thorough capture of healthcare utilizations, which can help balance out the effects of missing specific variables like AHI and BP. Third, the extended follow-up period (9 years) allowed us to monitor the participants over a substantial duration, which helps in capturing long-term health outcomes and healthcare utilizations. This long-term data collection can partially compensate for the absence of certain baseline measures by providing a more comprehensive view of patient health trajectories over time. Lastly, in our clinical setting, we had not collected PAP data until late 2012 and it was actually backward uploaded, and EHR implementation did not start until 2008, which led to expected unreliability and missing data from the initial period. We conducted an analysis to examine the data reliability across the timeline, which was published previously [<xref rid="B18" ref-type="bibr">18</xref>] and revisited in this project. Therefore, we specifically narrowed the follow-up years to mitigate potential biases associated with the early phase of Epic use, where data capture might have been less consistent. This approach ensures that our dataset is more complete and reliable, reducing the impact of missing data from the initial period of EHR implementation.</p><p>The use of EHR-derived data in research, while increasingly common, presents significant challenges. The ICD taxonomy does not consistently reflect clinical reality or how clinicians and coders interpret it. Coding practices can vary based on specialty or practice culture. As a result, focusing on individual PheCodes instead of sets of related PheCodes could lead to an underestimation of the true number of patients with a given comorbidity. Diagnostic codes, often used to justify procedures, are not always removed from the EHR when tests return negative results. Our algorithm requiring at least 2 instances of a code for a positive diagnosis helps limit false positives due to this issue. Our data collection started with the routine use of Epic at Penn, likely introducing a lag in capturing chronic conditions, leading to underestimated prevalences in the early years. We previously conducted an annual prevalence analysis to mitigate this bias [<xref rid="B18" ref-type="bibr">18</xref>]. For this project, we used a density ridge plot to visualize the distribution of numeric variables across 13 years (January 2008 to January 2021). The frequency of patient visits and the duration of observation in the healthcare system are generally associated with underlying health conditions. However, infrequent and sporadic visits may also reflect barriers to healthcare utilization or lower income, resulting in missed comorbidity ascertainment for these patients.</p><p>Over the years, there have been updates and refinements in the diagnostic criteria for OSA. Advances in sleep medicine, including improved diagnostic tools and techniques, may have led to increased detection and diagnosis of OSA cases. The introduction of HSAT and greater awareness among healthcare providers about the importance of diagnosing and treating OSA may have contributed to higher diagnostic rates, especially in the latter years of the study period. Tendency of broadly linking between our EHR systems would help to reduce lag time between real diagnosis time and being captured in EHR. Similarly, diagnostic criteria for HTN have been periodically updated. For instance, the American College of Cardiology/American Heart Association guidelines released in 2017 lowered the threshold for HTN diagnosis, which may have resulted in an increased number of HTN diagnoses in subsequent years [<xref rid="B28" ref-type="bibr">28</xref>]. Consider the impact of changes in clinical practices and coding standards by incorporating time-sensitive adjustments. This might involve segmenting the data by time periods or including interaction terms in the analysis to account for changes in diagnostic criteria or treatment practices. Regarding trending of advances in the treatment of OSA, including the use of PAP therapy, oral appliances, and surgical interventions, researcher would need to look at the whole picture and conduct a case-control studies (for instance, using propensity matching score) to account for all these developments may have affected the control of BP and the overall cardiovascular risk profile of patients.</p><p>Future studies should examine whether specific physiology including PAP usage that may interfere/affect other comorbidities which ultimately change the outcome of HTN developing over time. Similarly, these data should be compared across the previously identified subtypes to see whether differences in survival rate in different clusters. While we controlled for the baseline covariates including age, sex, race, and BMI, additional confounders (including differences in healthcare utilization) may explain some of the observed effects. Our future plans include creating a clinical prediction model based on the identified comorbidities and clinical variables, which could contribute to the geriatric prognosis indices on platforms like ePrognosis [<xref rid="B29" ref-type="bibr">29</xref>]. Integrating the coefficients from Aalen additive regression model into a scoring algorithm would be essential. Validation in a separate dataset is necessary to ensure accuracy. This model could help clinicians personalize counseling and monitoring for OSA patients regarding their HTN risk.</p></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>Our survival study provides a broader view of factors and diseases that modulate the temporal risk for developing HTN among OSA patients without preexisting HTN at first diagnosis of OSA. Our use of big data analysis and robust survival analysis approach provides greater understanding of the heterogeneous comorbidity burden associated with OSA and lays the groundwork for personalized medicine approaches. These approaches could be applied to other conditions to identify combinations that are predictive of developing a particular target condition.</p></sec></body><back><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Funding:</bold> None.</p></fn><fn fn-type="COI-statement"><p><bold>Competing interest:</bold> The authors declare that they have no competing interests.</p></fn><fn fn-type="other"><p><bold>Availability of data and materials:</bold> The data cannot be shared openly because it is considered property of the University of Pennsylvania.</p></fn><fn fn-type="other"><p><bold>Ethics approval and consent to participate:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Consent for publication:</bold> Not applicable.</p></fn><fn fn-type="con"><p><bold>Authors&#8217; contributions:</bold>
<list list-type="simple"><list-item><p><bold>Conceptualization:</bold> Te TT, Boland MR.</p></list-item><list-item><p><bold>Data curation:</bold> Te TT, Boland MR.</p></list-item><list-item><p><bold>Investigation:</bold> Te TT, Fung CH, Boland MR.</p></list-item><list-item><p><bold>Writing - original draft:</bold> Te TT, Fung CH, Boland MR.</p></list-item><list-item><p><bold>Writing - review &amp; editing:</bold> Te TT, Fung CH, Boland MR.</p></list-item></list></p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term>AHI</term><def><p>apnea-hypopnea index</p></def></def-item><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>BP</term><def><p>blood pressure</p></def></def-item><def-item><term>EHR</term><def><p>electronic health record</p></def></def-item><def-item><term>FDR</term><def><p>false discovery rate</p></def></def-item><def-item><term>GERD</term><def><p>gastroesophageal reflux disease</p></def></def-item><def-item><term>HSAT</term><def><p>home sleep apnea testing</p></def></def-item><def-item><term>HTN</term><def><p>hypertension</p></def></def-item><def-item><term>ICD</term><def><p>International Classification of Diseases</p></def></def-item><def-item><term>IQR</term><def><p>interquartile range</p></def></def-item><def-item><term>OSA</term><def><p>obstructive sleep apnea</p></def></def-item><def-item><term>PAP</term><def><p>positive airway pressure</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kryger</surname><given-names>MH</given-names></name><name name-style="western"><surname>Roth</surname><given-names>T</given-names></name><name name-style="western"><surname>Dement</surname><given-names>WC</given-names></name></person-group><source>Principles and practice of sleep medicine</source><edition>6th ed</edition><publisher-loc>Amsterdam</publisher-loc><publisher-name>Elsevier</publisher-name><year>2017</year></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leger</surname><given-names>D</given-names></name><name name-style="western"><surname>Bayon</surname><given-names>V</given-names></name><name name-style="western"><surname>Laaban</surname><given-names>JP</given-names></name><name name-style="western"><surname>Philip</surname><given-names>P</given-names></name></person-group><article-title>Impact of sleep apnea on economics</article-title><source>Sleep Med Rev</source><year>2012</year><volume>16</volume><fpage>455</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">22244357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.smrv.2011.10.001</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>KP</given-names></name><name name-style="western"><surname>Terris</surname><given-names>DJ</given-names></name></person-group><article-title>Screening for obstructive sleep apnea: an evidence-based analysis</article-title><source>Am J Otolaryngol</source><year>2006</year><volume>27</volume><fpage>112</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">16500475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjoto.2005.09.002</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marshall</surname><given-names>NS</given-names></name><name name-style="western"><surname>Wong</surname><given-names>KK</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>SR</given-names></name><name name-style="western"><surname>Knuiman</surname><given-names>MW</given-names></name><name name-style="western"><surname>Grunstein</surname><given-names>RR</given-names></name></person-group><article-title>Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the Busselton Health Study cohort</article-title><source>J Clin Sleep Med</source><year>2014</year><volume>10</volume><fpage>355</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">24733978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5664/jcsm.3600</pub-id><pub-id pub-id-type="pmcid">PMC3960375</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>AR</given-names></name><name name-style="western"><surname>Patel</surname><given-names>AR</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Khawaja</surname><given-names>I</given-names></name></person-group><article-title>The association of obstructive sleep apnea and hypertension</article-title><source>Cureus</source><year>2019</year><volume>11</volume><elocation-id>e4858</elocation-id><pub-id pub-id-type="pmid">31410341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.4858</pub-id><pub-id pub-id-type="pmcid">PMC6684296</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirrakhimov</surname><given-names>AE</given-names></name></person-group><article-title>Non drowsy obstructive sleep apnea as a potential cause of resistant hypertension: a case report</article-title><source>BMC Pulm Med</source><year>2012</year><volume>12</volume><fpage>16</fpage><pub-id pub-id-type="pmid">22533344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2466-12-16</pub-id><pub-id pub-id-type="pmcid">PMC3355001</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarokhani</surname><given-names>M</given-names></name><name name-style="western"><surname>Goli</surname><given-names>M</given-names></name><name name-style="western"><surname>Salarvand</surname><given-names>S</given-names></name><name name-style="western"><surname>Ghanei Gheshlagh</surname><given-names>R</given-names></name></person-group><article-title>The prevalence of sleep apnea in Iran: a systematic review and meta-analysis</article-title><source>Tanaffos</source><year>2019</year><volume>18</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">31423134</pub-id><pub-id pub-id-type="pmcid">PMC6690329</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>M</given-names></name><name name-style="western"><surname>Makati</surname><given-names>D</given-names></name><name name-style="western"><surname>Akbar</surname><given-names>S</given-names></name></person-group><article-title>Review of and updates on hypertension in obstructive sleep apnea</article-title><source>Int J Hypertens</source><year>2017</year><volume>2017</volume><elocation-id>1848375</elocation-id><pub-id pub-id-type="pmid">29147581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2017/1848375</pub-id><pub-id pub-id-type="pmcid">PMC5632858</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Floras</surname><given-names>JS</given-names></name></person-group><article-title>Hypertension and sleep apnea</article-title><source>Can J Cardiol</source><year>2015</year><volume>31</volume><fpage>889</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">26112299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cjca.2015.05.003</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Connor</surname><given-names>GT</given-names></name><name name-style="western"><surname>Caffo</surname><given-names>B</given-names></name><name name-style="western"><surname>Newman</surname><given-names>AB</given-names></name><name name-style="western"><surname>Quan</surname><given-names>SF</given-names></name><name name-style="western"><surname>Rapoport</surname><given-names>DM</given-names></name><name name-style="western"><surname>Redline</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prospective study of sleep-disordered breathing and hypertension: the Sleep Heart Health Study</article-title><source>Am J Respir Crit Care Med</source><year>2009</year><volume>179</volume><fpage>1159</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">19264976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.200712-1809OC</pub-id><pub-id pub-id-type="pmcid">PMC2695498</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cano-Pumarega</surname><given-names>I</given-names></name><name name-style="western"><surname>Dur&#225;n-Cantolla</surname><given-names>J</given-names></name><name name-style="western"><surname>Aizpuru</surname><given-names>F</given-names></name><name name-style="western"><surname>Miranda-Serrano</surname><given-names>E</given-names></name><name name-style="western"><surname>Rubio</surname><given-names>R</given-names></name><name name-style="western"><surname>Mart&#237;nez-Null</surname><given-names>C</given-names></name><etal/></person-group><article-title>Obstructive sleep apnea and systemic hypertension: longitudinal study in the general population: the Vitoria Sleep Cohort</article-title><source>Am J Respir Crit Care Med</source><year>2011</year><volume>184</volume><fpage>1299</fpage><lpage>1304</lpage><pub-id pub-id-type="pmid">21868499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201101-0130OC</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marin</surname><given-names>JM</given-names></name><name name-style="western"><surname>Agusti</surname><given-names>A</given-names></name><name name-style="western"><surname>Villar</surname><given-names>I</given-names></name><name name-style="western"><surname>Forner</surname><given-names>M</given-names></name><name name-style="western"><surname>Nieto</surname><given-names>D</given-names></name><name name-style="western"><surname>Carrizo</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Association between treated and untreated obstructive sleep apnea and risk of hypertension</article-title><source>JAMA</source><year>2012</year><volume>307</volume><fpage>2169</fpage><lpage>2176</lpage><pub-id pub-id-type="pmid">22618924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2012.3418</pub-id><pub-id pub-id-type="pmcid">PMC4657563</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hla</surname><given-names>KM</given-names></name><name name-style="western"><surname>Young</surname><given-names>T</given-names></name><name name-style="western"><surname>Finn</surname><given-names>L</given-names></name><name name-style="western"><surname>Peppard</surname><given-names>PE</given-names></name><name name-style="western"><surname>Szklo-Coxe</surname><given-names>M</given-names></name><name name-style="western"><surname>Stubbs</surname><given-names>M</given-names></name></person-group><article-title>Longitudinal association of sleep-disordered breathing and nondipping of nocturnal blood pressure in the Wisconsin Sleep Cohort Study</article-title><source>Sleep</source><year>2008</year><volume>31</volume><fpage>795</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">18548823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/sleep/31.6.795</pub-id><pub-id pub-id-type="pmcid">PMC2442417</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peppard</surname><given-names>PE</given-names></name><name name-style="western"><surname>Young</surname><given-names>T</given-names></name><name name-style="western"><surname>Palta</surname><given-names>M</given-names></name><name name-style="western"><surname>Skatrud</surname><given-names>J</given-names></name></person-group><article-title>Prospective study of the association between sleep-disordered breathing and hypertension</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><fpage>1378</fpage><lpage>1384</lpage><pub-id pub-id-type="pmid">10805822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM200005113421901</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fayyad</surname><given-names>U</given-names></name><name name-style="western"><surname>Piatetsky-Shapiro</surname><given-names>G</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>P</given-names></name></person-group><article-title>From data mining to knowledge discovery in databases</article-title><source>AI Mag</source><year>1996</year><volume>17</volume><fpage>37</fpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazzotti</surname><given-names>DR</given-names></name></person-group><article-title>Landscape of biomedical informatics standards and terminologies for clinical sleep medicine research: a systematic review</article-title><source>Sleep Med Rev</source><year>2021</year><volume>60</volume><elocation-id>101529</elocation-id><pub-id pub-id-type="pmid">34455108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.smrv.2021.101529</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;pin</surname><given-names>JL</given-names></name><name name-style="western"><surname>Bailly</surname><given-names>S</given-names></name><name name-style="western"><surname>Tamisier</surname><given-names>R</given-names></name></person-group><article-title>Big data in sleep apnoea: opportunities and challenges</article-title><source>Respirology</source><year>2020</year><volume>25</volume><fpage>486</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">31411796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/resp.13669</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Te</surname><given-names>TT</given-names></name><name name-style="western"><surname>Keenan</surname><given-names>BT</given-names></name><name name-style="western"><surname>Veatch</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Boland</surname><given-names>MR</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>RA</given-names></name><name name-style="western"><surname>Pack</surname><given-names>AI</given-names></name></person-group><article-title>Identifying clusters of patient comorbidities associated with obstructive sleep apnea using electronic health records</article-title><source>J Clin Sleep Med</source><year>2024</year><volume>20</volume><fpage>521</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">38054454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5664/jcsm.10930</pub-id><pub-id pub-id-type="pmcid">PMC10985292</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keenan</surname><given-names>BT</given-names></name><name name-style="western"><surname>Kirchner</surname><given-names>HL</given-names></name><name name-style="western"><surname>Veatch</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Borthwick</surname><given-names>KM</given-names></name><name name-style="western"><surname>Davenport</surname><given-names>VA</given-names></name><name name-style="western"><surname>Feemster</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Multisite validation of a simple electronic health record algorithm for identifying diagnosed obstructive sleep apnea</article-title><source>J Clin Sleep Med</source><year>2020</year><volume>16</volume><fpage>175</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">31992429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5664/jcsm.8160</pub-id><pub-id pub-id-type="pmcid">PMC7053021</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aalen</surname><given-names>OO</given-names></name></person-group><article-title>A linear regression model for the analysis of life times</article-title><source>Stat Med</source><year>1989</year><volume>8</volume><fpage>907</fpage><lpage>925</lpage><pub-id pub-id-type="pmid">2678347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.4780080803</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aalen</surname><given-names>OO</given-names></name></person-group><article-title>Further results on the non-parametric linear regression model in survival analysis</article-title><source>Stat Med</source><year>1993</year><volume>12</volume><fpage>1569</fpage><lpage>1588</lpage><pub-id pub-id-type="pmid">8235179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.4780121705</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Therneau</surname><given-names>TM</given-names></name><name name-style="western"><surname>Grambsch</surname><given-names>PM</given-names></name></person-group><source>Modeling survival data: extending the Cox model</source><publisher-loc>Berlin</publisher-loc><publisher-name>Springer</publisher-name><year>2020</year></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Baldassaro</surname><given-names>M</given-names></name></person-group><source>Sampler: sample design, drawing &amp; data analysis using data frames. R package ver. 0.2.4. R Foundation for Statistical Computing</source><year>2019</year><date-in-citation content-type="access-date">Accessed 30 Jun 2024</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://CRAN.R-project.org/package=sampler" ext-link-type="uri">https://CRAN.R-project.org/package=sampler</ext-link></comment></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapur</surname><given-names>VK</given-names></name><name name-style="western"><surname>Auckley</surname><given-names>DH</given-names></name><name name-style="western"><surname>Chowdhuri</surname><given-names>S</given-names></name><name name-style="western"><surname>Kuhlmann</surname><given-names>DC</given-names></name><name name-style="western"><surname>Mehra</surname><given-names>R</given-names></name><name name-style="western"><surname>Ramar</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline</article-title><source>J Clin Sleep Med</source><year>2017</year><volume>13</volume><fpage>479</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">28162150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5664/jcsm.6506</pub-id><pub-id pub-id-type="pmcid">PMC5337595</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paschou</surname><given-names>SA</given-names></name><name name-style="western"><surname>Bletsa</surname><given-names>E</given-names></name><name name-style="western"><surname>Saltiki</surname><given-names>K</given-names></name><name name-style="western"><surname>Kazakou</surname><given-names>P</given-names></name><name name-style="western"><surname>Kantreva</surname><given-names>K</given-names></name><name name-style="western"><surname>Katsaounou</surname><given-names>P</given-names></name><etal/></person-group><article-title>Sleep apnea and cardiovascular risk in patients with prediabetes and type 2 diabetes</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><fpage>4989</fpage><pub-id pub-id-type="pmid">36501019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu14234989</pub-id><pub-id pub-id-type="pmcid">PMC9741445</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valvi</surname><given-names>N</given-names></name><name name-style="western"><surname>McFarlane</surname><given-names>T</given-names></name><name name-style="western"><surname>Allen</surname><given-names>KS</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>BE</given-names></name></person-group><article-title>Identification of hypertension in electronic health records through computable phenotype development and validation for use in public health surveillance: retrospective study</article-title><source>JMIR Form Res</source><year>2023</year><volume>7</volume><elocation-id>e46413</elocation-id><pub-id pub-id-type="pmid">38150296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/46413</pub-id><pub-id pub-id-type="pmcid">PMC10782284</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fattal</surname><given-names>D</given-names></name><name name-style="western"><surname>Hester</surname><given-names>S</given-names></name><name name-style="western"><surname>Wendt</surname><given-names>L</given-names></name></person-group><article-title>Body weight and obstructive sleep apnea: a mathematical relationship between body mass index and apnea-hypopnea index in veterans</article-title><source>J Clin Sleep Med</source><year>2022</year><volume>18</volume><fpage>2723</fpage><lpage>2729</lpage><pub-id pub-id-type="pmid">35929587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5664/jcsm.10190</pub-id><pub-id pub-id-type="pmcid">PMC9713905</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whelton</surname><given-names>PK</given-names></name><name name-style="western"><surname>Carey</surname><given-names>RM</given-names></name><name name-style="western"><surname>Aronow</surname><given-names>WS</given-names></name><name name-style="western"><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Collins</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Dennison Himmelfarb</surname><given-names>C</given-names></name><etal/></person-group><article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</article-title><source>J Am Coll Cardiol</source><year>2018</year><volume>71</volume><fpage>e127</fpage><lpage>e248</lpage><pub-id pub-id-type="pmid">29146535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2017.11.006</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="book"><collab>ePrognosis</collab><source>What is ePrognosis?</source><publisher-name>ePrognosis</publisher-name><year>2024</year><date-in-citation content-type="access-date">Accessed 30 Jun 2024</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://eprognosis.ucsf.edu/about.php" ext-link-type="uri">https://eprognosis.ucsf.edu/about.php</ext-link></comment></element-citation></ref></ref-list></back></article></pmc-articleset>